We report here the first case to add amprenavir to the growing list of antiretroviral drugs associated with urinary stones. The first reported case of a nelfinavir urinary stone was reported in 2002 in a 37-year-old HIV-infected woman. In September 2007, the same female patient was referred to our department with recent onset of right flank pain and recurrent urinary tract infections. Abdominal computed tomography revealed three obstructing stones in the distal right ureter, another stone in the right renal pelvis with hydronephrosis and a stone in the left kidney. After stone retrieval, analysis of the stone by liquid chromatography with mass spectrometry revealed a stone composition of 95% unmodified amprenavir and 5% ritonavir.
References
1.
JohnH., MμllerN.J., OpravilM., HauriD.Indinavir urinary stones as origin of upper urinary tract obstruction.Urol Int1997; 59: 257–259.
SutherlandS.E., ReigleM.D., SeftelA.D., ResnickM.I.Protease inhibitors and urolithiasis.J Urol1997; 158: 31–33.
6.
MorantJ., RuppannerH.Arzneimittelkompendium der Schweiz 2007, 28th Edition. Basel, Switzerland: Documed, AG, pp. 3384–3388, 2007.
7.
MalavaudB., DinhB, BonnetE., IzopetJ., PayenJ.L., MarchouB.Increased incidence of indinavir nephrolithiasis in patients with hepatits B or C virus infection.Antivir Ther2000; 5: 3–5.
